Oncosil Medical Ltd has released a press release.
Receipt of $2.8m R&D Tax Incentive Refund
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from OncoSil Medical
- Investor Update
- OncoSil receives Malaysian regulatory approval
- Preliminary Final Report - Appendix 4E Announcement
- HDE filing submitted in US for Bile Duct Cancer treatment
- OncoSil presents clinical data at ESMO World Congress
Later from OncoSil Medical
- Positive PanCO trial update on resected cohort
- OncoSil achieves first commercial sale
- OncoSil receives Swiss regulatory approval
- Termination of Mr Daniel Kenny as Chief Executive Officer
- OncoSil FY21 half yearly review
Follow OncoSil Medical into a list and get an email when it puts out news.
Follow OncoSil Medical